ReShape Lifesciences (RSLS) Competitors

ReShape Lifesciences (NASDAQ:RSLS) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Does the MarketBeat Community favor RSLS or ABT?

Abbott Laboratories received 554 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 69.90% of users gave Abbott Laboratories an outperform vote while only 66.00% of users gave ReShape Lifesciences an outperform vote.

Company	Underperform	Outperform
ReShape Lifesciences	Outperform Votes 398 66.00%	Underperform Votes 205 34.00%
Abbott Laboratories	Outperform Votes 952 69.90%	Underperform Votes 410 30.10%

Does the media refer more to RSLS or ABT?

In the previous week, Abbott Laboratories had 78 more articles in the media than ReShape Lifesciences. MarketBeat recorded 79 mentions for Abbott Laboratories and 1 mentions for ReShape Lifesciences. Abbott Laboratories' average media sentiment score of 1.39 beat ReShape Lifesciences' score of -0.67 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ReShape Lifesciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Abbott Laboratories	61 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, RSLS or ABT?

ReShape Lifesciences has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Do analysts rate RSLS or ABT?

Abbott Laboratories has a consensus price target of $142.61, suggesting a potential upside of 7.02%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abbott Laboratories	0 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.76

Is RSLS or ABT more profitable?

Abbott Laboratories has a net margin of 31.89% compared to ReShape Lifesciences' net margin of -48.26%. Abbott Laboratories' return on equity of 19.01% beat ReShape Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-48.26%	-251.90%	-59.49%
Abbott Laboratories	31.89%	19.01%	10.82%

Which has preferable valuation and earnings, RSLS or ABT?

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences. ReShape Lifesciences is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$8.01M	0.76	-$7.13M	-$193.23	-0.01
Abbott Laboratories	$41.95B	5.53	$13.40B	$7.71	17.28

Do insiders & institutionals believe in RSLS or ABT?

22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.0% of ReShape Lifesciences shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Abbott Laboratories beats ReShape Lifesciences on 18 of the 19 factors compared between the two stocks.